PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.23%
Revenue growth above 1.5x AVGO's 2.91%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
5.71%
Gross profit growth similar to AVGO's 5.47%. Walter Schloss would assume both firms track common industry trends.
0.51%
EBIT growth below 50% of AVGO's 20.38%. Michael Burry would suspect deeper competitive or cost structure issues.
6.95%
Operating income growth under 50% of AVGO's 20.38%. Michael Burry would be concerned about deeper cost or sales issues.
3.85%
Net income growth comparable to AVGO's 4.08%. Walter Schloss might see both following similar market or cost trajectories.
3.83%
EPS growth 1.25-1.5x AVGO's 3.23%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
3.89%
Diluted EPS growth 1.25-1.5x AVGO's 3.45%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.33%
Share count expansion well above AVGO's 0.49%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.32%
Diluted share count expanding well above AVGO's 0.47%. Michael Burry would fear significant dilution to existing owners' stakes.
-0.01%
Dividend reduction while AVGO stands at 10.07%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-12.94%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-19.39%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
60.04%
10Y revenue/share CAGR under 50% of AVGO's 617.66%. Michael Burry would suspect a lasting competitive disadvantage.
55.67%
5Y revenue/share CAGR under 50% of AVGO's 155.11%. Michael Burry would suspect a significant competitive gap or product weakness.
20.69%
3Y revenue/share CAGR at 75-90% of AVGO's 25.54%. Bill Ackman would expect new product strategies to close the gap.
353.80%
10Y OCF/share CAGR under 50% of AVGO's 2655.74%. Michael Burry would worry about a persistent underperformance in cash creation.
269.23%
5Y OCF/share CAGR at 75-90% of AVGO's 345.86%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
77.37%
3Y OCF/share CAGR similar to AVGO's 85.64%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
233.16%
Below 50% of AVGO's 586.81%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
169.17%
5Y net income/share CAGR 1.25-1.5x AVGO's 148.15%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
36.82%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
21.69%
Below 50% of AVGO's 765.82%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
13.46%
Below 50% of AVGO's 218.15%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
1.85%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
677.64%
Below 50% of AVGO's 5283.33%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
167.94%
Below 50% of AVGO's 758.63%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
64.02%
3Y dividend/share CAGR at 50-75% of AVGO's 105.36%. Martin Whitman might see a weaker short-term approach to distributing cash.
12.02%
AR growth well above AVGO's 9.88%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.32%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
1.49%
Similar asset growth to AVGO's 1.37%. Walter Schloss finds parallel expansions or investment rates.
10.30%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-12.21%
We’re deleveraging while AVGO stands at 2.12%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.52%
Our R&D shrinks while AVGO invests at 2.45%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.78%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.